Nwam LLC Trims Stock Holdings in Gilead Sciences, Inc. $GILD

Nwam LLC lowered its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 12.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,307 shares of the biopharmaceutical company’s stock after selling 1,857 shares during the period. Nwam LLC’s holdings in Gilead Sciences were worth $1,527,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Price T Rowe Associates Inc. MD raised its holdings in Gilead Sciences by 314.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after acquiring an additional 11,156,382 shares during the period. Nuveen LLC bought a new position in shares of Gilead Sciences in the first quarter worth $620,415,000. Kingstone Capital Partners Texas LLC purchased a new position in shares of Gilead Sciences in the second quarter valued at $238,083,000. Los Angeles Capital Management LLC grew its position in shares of Gilead Sciences by 422.6% in the first quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company’s stock valued at $282,706,000 after purchasing an additional 2,040,261 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Gilead Sciences by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock valued at $13,162,606,000 after purchasing an additional 1,942,433 shares during the period. 83.67% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Sanford C. Bernstein restated an “outperform” rating on shares of Gilead Sciences in a research note on Monday, November 3rd. Daiwa Capital Markets upgraded Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price target on the stock in a research report on Tuesday, August 19th. UBS Group raised their price objective on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a research report on Friday, August 8th. Wolfe Research boosted their price objective on shares of Gilead Sciences from $135.00 to $140.00 and gave the company an “outperform” rating in a research note on Thursday, October 23rd. Finally, BMO Capital Markets upped their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an “outperform” rating in a report on Monday, October 20th. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $128.27.

Gilead Sciences Stock Up 3.7%

GILD stock opened at $122.56 on Wednesday. The company’s 50 day moving average is $116.79 and its 200 day moving average is $112.48. The stock has a market cap of $152.07 billion, a price-to-earnings ratio of 24.41, a price-to-earnings-growth ratio of 0.81 and a beta of 0.32. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a 1-year low of $86.08 and a 1-year high of $124.61.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The business had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be given a $0.79 dividend. The ex-dividend date is Monday, December 15th. This represents a $3.16 annualized dividend and a yield of 2.6%. Gilead Sciences’s payout ratio is 48.99%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the sale, the chief executive officer owned 591,203 shares in the company, valued at $66,013,726.98. This trade represents a 1.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the transaction, the insider owned 114,168 shares of the company’s stock, valued at $13,532,333.04. The trade was a 19.70% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 71,500 shares of company stock valued at $8,336,040 over the last 90 days. 0.27% of the stock is owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.